EXPRESSION OF CD143 ON CD34-POSITIVE CELLS IN PERIPHERAL BLOOD AND APHERESIS PRODUCTS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT THE MOBILIZATION OF PERIPHERAL BLOOD PROGENITOR CELLS (PBPCS)
(Abstract release date: 05/19/16)
EHA Library. Kanaeva M. 06/09/16; 133096; E1547
Dr. Madina Kanaeva
Contributions
Contributions
Abstract
Abstract: E1547
Type: Eposter Presentation
Background
Angiotensin converting enzyme (CD143) is a part of the renin-angiotensin system catalyzing the cleavage of angiotensin I to angiotensin II. CD143 is expressed in blood-forming tissues of the human embryo: para-aortic splanchnopleura, yolk sac, aorta-gonad-mesonephros, liver and bone marrow. Transplantation into NOD/SCID mice and cultivation have shown that CD34+/CD143+ cell progenitors, but not CD34+/CD143-, sustain multilineage hematopoietic cell engraftment and have long-term culture-initiating cell potential.
Aims
To estimate of CD143 expression on CD34+ cells in peripheral blood and apheresis products in patients with hematological malignancies before and after the mobilization of PBPCs.
Methods
The study included 31 patients: 16 women and 15 men aged 22-68 years old (median 52). 29 patients were diagnosed with multiple myeloma and 2 - Hodgkin's lymphoma. Analysis of CD34+ cells was performed by flow cytometry (FACSCantoII, Becton Dickinson) using monoclonal antibodies: CD34 PE, CD45 FITC, and CD143 APC (Becton Dickinson). The percentage of CD34+ among CD45+ cells and the percentage of CD34+/CD143+ in CD34+ population were calculated in peripheral blood of patients before mobilization and in peripheral blood and apheresis products on the day of leukapheresis. The mobilization was performed with cytotoxic chemotherapy (cyclophosphamide - 4 g/m2 - 24 patients, patient - 2 DHAP) + 5 mg/kg G-CSF (CC+G-CSF) in 26 cases and with G-CSF (10 mg/kg) only - in 5 cases. The control group included peripheral blood samples from 10 healthy donors without mobilization.
Results
The percentage of CD34+ cells in peripheral blood before mobilization from all patients was 0.03±0.01% compared to healthy control group with 0.024±0.004% (p=0.62). The percentage of CD34+/CD143+ was 12.33±1.55% (3.42±1.43% in healthy donors, p=0.004).After the mobilization percentage of CD34+ cells in peripheral blood was 0.08±0.05% when mobilization was performed with G-CSF, and in case of using CC+G-CSF the percentage of CD34+ was 0.83±0.18% (p=0.09). The percentage of CD34+/CD143+ cells with G-CSF mobilization was 28.32±4.06%, compared to 46.07±2.96% (p=0.01) in patients with CC+G-CSF mobilization. The apheresis products contained 0.36±0.11% of CD34+ cells after mobilization with G-CSF, and 1.55±0.25% of CD34+ cells after mobilization with CC+G-CSF (p=0.048). The percentage of CD34+/CD143+ cells in apheresis products was 29.16±5.99% when mobilization was carried out with G-CSF and 47.96±2.77% (p=0.01) in patients with CC+G-CSF mobilization.
Conclusion
Thus, increase of CD34+/CD143+ cell number in peripheral blood and apheresis products after mobilization has been shown. Increase of CD34+/CD143+ cells in patients after mobilization of PBPCs with chemotherapy and G-CSF was significantly greater in contrast to the mobilization with G-CSF alone. Patients with hematological malignancies before mobilization had higher percentage of CD34+/CD143+ cells in peripheral blood then healthy donors that may be due to previous chemotherapy.
Session topic: E-poster
Keyword(s): APC, CD34+ cells, Mobilization, Progenitor cell
Type: Eposter Presentation
Background
Angiotensin converting enzyme (CD143) is a part of the renin-angiotensin system catalyzing the cleavage of angiotensin I to angiotensin II. CD143 is expressed in blood-forming tissues of the human embryo: para-aortic splanchnopleura, yolk sac, aorta-gonad-mesonephros, liver and bone marrow. Transplantation into NOD/SCID mice and cultivation have shown that CD34+/CD143+ cell progenitors, but not CD34+/CD143-, sustain multilineage hematopoietic cell engraftment and have long-term culture-initiating cell potential.
Aims
To estimate of CD143 expression on CD34+ cells in peripheral blood and apheresis products in patients with hematological malignancies before and after the mobilization of PBPCs.
Methods
The study included 31 patients: 16 women and 15 men aged 22-68 years old (median 52). 29 patients were diagnosed with multiple myeloma and 2 - Hodgkin's lymphoma. Analysis of CD34+ cells was performed by flow cytometry (FACSCantoII, Becton Dickinson) using monoclonal antibodies: CD34 PE, CD45 FITC, and CD143 APC (Becton Dickinson). The percentage of CD34+ among CD45+ cells and the percentage of CD34+/CD143+ in CD34+ population were calculated in peripheral blood of patients before mobilization and in peripheral blood and apheresis products on the day of leukapheresis. The mobilization was performed with cytotoxic chemotherapy (cyclophosphamide - 4 g/m2 - 24 patients, patient - 2 DHAP) + 5 mg/kg G-CSF (CC+G-CSF) in 26 cases and with G-CSF (10 mg/kg) only - in 5 cases. The control group included peripheral blood samples from 10 healthy donors without mobilization.
Results
The percentage of CD34+ cells in peripheral blood before mobilization from all patients was 0.03±0.01% compared to healthy control group with 0.024±0.004% (p=0.62). The percentage of CD34+/CD143+ was 12.33±1.55% (3.42±1.43% in healthy donors, p=0.004).After the mobilization percentage of CD34+ cells in peripheral blood was 0.08±0.05% when mobilization was performed with G-CSF, and in case of using CC+G-CSF the percentage of CD34+ was 0.83±0.18% (p=0.09). The percentage of CD34+/CD143+ cells with G-CSF mobilization was 28.32±4.06%, compared to 46.07±2.96% (p=0.01) in patients with CC+G-CSF mobilization. The apheresis products contained 0.36±0.11% of CD34+ cells after mobilization with G-CSF, and 1.55±0.25% of CD34+ cells after mobilization with CC+G-CSF (p=0.048). The percentage of CD34+/CD143+ cells in apheresis products was 29.16±5.99% when mobilization was carried out with G-CSF and 47.96±2.77% (p=0.01) in patients with CC+G-CSF mobilization.
Conclusion
Thus, increase of CD34+/CD143+ cell number in peripheral blood and apheresis products after mobilization has been shown. Increase of CD34+/CD143+ cells in patients after mobilization of PBPCs with chemotherapy and G-CSF was significantly greater in contrast to the mobilization with G-CSF alone. Patients with hematological malignancies before mobilization had higher percentage of CD34+/CD143+ cells in peripheral blood then healthy donors that may be due to previous chemotherapy.
Session topic: E-poster
Keyword(s): APC, CD34+ cells, Mobilization, Progenitor cell
Abstract: E1547
Type: Eposter Presentation
Background
Angiotensin converting enzyme (CD143) is a part of the renin-angiotensin system catalyzing the cleavage of angiotensin I to angiotensin II. CD143 is expressed in blood-forming tissues of the human embryo: para-aortic splanchnopleura, yolk sac, aorta-gonad-mesonephros, liver and bone marrow. Transplantation into NOD/SCID mice and cultivation have shown that CD34+/CD143+ cell progenitors, but not CD34+/CD143-, sustain multilineage hematopoietic cell engraftment and have long-term culture-initiating cell potential.
Aims
To estimate of CD143 expression on CD34+ cells in peripheral blood and apheresis products in patients with hematological malignancies before and after the mobilization of PBPCs.
Methods
The study included 31 patients: 16 women and 15 men aged 22-68 years old (median 52). 29 patients were diagnosed with multiple myeloma and 2 - Hodgkin's lymphoma. Analysis of CD34+ cells was performed by flow cytometry (FACSCantoII, Becton Dickinson) using monoclonal antibodies: CD34 PE, CD45 FITC, and CD143 APC (Becton Dickinson). The percentage of CD34+ among CD45+ cells and the percentage of CD34+/CD143+ in CD34+ population were calculated in peripheral blood of patients before mobilization and in peripheral blood and apheresis products on the day of leukapheresis. The mobilization was performed with cytotoxic chemotherapy (cyclophosphamide - 4 g/m2 - 24 patients, patient - 2 DHAP) + 5 mg/kg G-CSF (CC+G-CSF) in 26 cases and with G-CSF (10 mg/kg) only - in 5 cases. The control group included peripheral blood samples from 10 healthy donors without mobilization.
Results
The percentage of CD34+ cells in peripheral blood before mobilization from all patients was 0.03±0.01% compared to healthy control group with 0.024±0.004% (p=0.62). The percentage of CD34+/CD143+ was 12.33±1.55% (3.42±1.43% in healthy donors, p=0.004).After the mobilization percentage of CD34+ cells in peripheral blood was 0.08±0.05% when mobilization was performed with G-CSF, and in case of using CC+G-CSF the percentage of CD34+ was 0.83±0.18% (p=0.09). The percentage of CD34+/CD143+ cells with G-CSF mobilization was 28.32±4.06%, compared to 46.07±2.96% (p=0.01) in patients with CC+G-CSF mobilization. The apheresis products contained 0.36±0.11% of CD34+ cells after mobilization with G-CSF, and 1.55±0.25% of CD34+ cells after mobilization with CC+G-CSF (p=0.048). The percentage of CD34+/CD143+ cells in apheresis products was 29.16±5.99% when mobilization was carried out with G-CSF and 47.96±2.77% (p=0.01) in patients with CC+G-CSF mobilization.
Conclusion
Thus, increase of CD34+/CD143+ cell number in peripheral blood and apheresis products after mobilization has been shown. Increase of CD34+/CD143+ cells in patients after mobilization of PBPCs with chemotherapy and G-CSF was significantly greater in contrast to the mobilization with G-CSF alone. Patients with hematological malignancies before mobilization had higher percentage of CD34+/CD143+ cells in peripheral blood then healthy donors that may be due to previous chemotherapy.
Session topic: E-poster
Keyword(s): APC, CD34+ cells, Mobilization, Progenitor cell
Type: Eposter Presentation
Background
Angiotensin converting enzyme (CD143) is a part of the renin-angiotensin system catalyzing the cleavage of angiotensin I to angiotensin II. CD143 is expressed in blood-forming tissues of the human embryo: para-aortic splanchnopleura, yolk sac, aorta-gonad-mesonephros, liver and bone marrow. Transplantation into NOD/SCID mice and cultivation have shown that CD34+/CD143+ cell progenitors, but not CD34+/CD143-, sustain multilineage hematopoietic cell engraftment and have long-term culture-initiating cell potential.
Aims
To estimate of CD143 expression on CD34+ cells in peripheral blood and apheresis products in patients with hematological malignancies before and after the mobilization of PBPCs.
Methods
The study included 31 patients: 16 women and 15 men aged 22-68 years old (median 52). 29 patients were diagnosed with multiple myeloma and 2 - Hodgkin's lymphoma. Analysis of CD34+ cells was performed by flow cytometry (FACSCantoII, Becton Dickinson) using monoclonal antibodies: CD34 PE, CD45 FITC, and CD143 APC (Becton Dickinson). The percentage of CD34+ among CD45+ cells and the percentage of CD34+/CD143+ in CD34+ population were calculated in peripheral blood of patients before mobilization and in peripheral blood and apheresis products on the day of leukapheresis. The mobilization was performed with cytotoxic chemotherapy (cyclophosphamide - 4 g/m2 - 24 patients, patient - 2 DHAP) + 5 mg/kg G-CSF (CC+G-CSF) in 26 cases and with G-CSF (10 mg/kg) only - in 5 cases. The control group included peripheral blood samples from 10 healthy donors without mobilization.
Results
The percentage of CD34+ cells in peripheral blood before mobilization from all patients was 0.03±0.01% compared to healthy control group with 0.024±0.004% (p=0.62). The percentage of CD34+/CD143+ was 12.33±1.55% (3.42±1.43% in healthy donors, p=0.004).After the mobilization percentage of CD34+ cells in peripheral blood was 0.08±0.05% when mobilization was performed with G-CSF, and in case of using CC+G-CSF the percentage of CD34+ was 0.83±0.18% (p=0.09). The percentage of CD34+/CD143+ cells with G-CSF mobilization was 28.32±4.06%, compared to 46.07±2.96% (p=0.01) in patients with CC+G-CSF mobilization. The apheresis products contained 0.36±0.11% of CD34+ cells after mobilization with G-CSF, and 1.55±0.25% of CD34+ cells after mobilization with CC+G-CSF (p=0.048). The percentage of CD34+/CD143+ cells in apheresis products was 29.16±5.99% when mobilization was carried out with G-CSF and 47.96±2.77% (p=0.01) in patients with CC+G-CSF mobilization.
Conclusion
Thus, increase of CD34+/CD143+ cell number in peripheral blood and apheresis products after mobilization has been shown. Increase of CD34+/CD143+ cells in patients after mobilization of PBPCs with chemotherapy and G-CSF was significantly greater in contrast to the mobilization with G-CSF alone. Patients with hematological malignancies before mobilization had higher percentage of CD34+/CD143+ cells in peripheral blood then healthy donors that may be due to previous chemotherapy.
Session topic: E-poster
Keyword(s): APC, CD34+ cells, Mobilization, Progenitor cell
{{ help_message }}
{{filter}}